R. J. Laib

Species differences in butadiene metabolism between mice and rats evaluated by inhalation pharmacokinetics

Metabolism of 1,3-butadiene to 1,2-epoxybutene-3 in rats follows saturation kinetics. Comparative investigation of inhalation pharmacokinetics in mice also revealed a saturation pattern. For both species “linear” pharmacokinetics apply at exposure concentrations below 1000 ppm 1,3-butadiene; saturation of butadiene metabolism is observed at atmospheric concentrations of about 2000 ppm.For mice metabolic clearance per kg body weight in the lower concentration range where first order metabolism applies was 7300ml×h−1 (rat: 4500 ml×h−1). Maximal metabolic elimination rate (Vmax) was 400 μmol×h−1 ×kg−1 (rat: 220 μmol ×h−1×kg−1). This shows that 1,3-butadiene is metabolized by mice at higher rates compared to rats.Based on these investigations, the metabolic elimination rates of butadiene in both species were calculated for the exposure concentrations applied in two inhalation bioassays with rats and with mice. The results show that the higher rate of butadiene metabolism in mice when compared to rats may only in part be responsible for the considerable difference in the susceptibility of both species to butadiene-induced carcinogenesis.

Alkylation of nuclear proteins and dna after exposure of rats and mice to [1,4-14C]1,3-butadiene

B6C3F1 mice and Wistar rats were exposed to [1,4-14C]1,3-butadiene in a closed exposure system. Based on body weight, mice metabolized the test compound at about twice the rate, compared to rats. Nucleoproteins and DNA were isolated from the livers of the animals and covalent binding of [14C]-butadiene-derived radioactivity was determined. In both species comparable amounts of radioactivity were covalently bound to liver DNA. Covalent binding to mouse-liver nucleoproteins was twice as high as in rats and thus it paralleled the higher metabolic rate for butadiene in this species.

Inhalation pharmacokinetics of 1,2-epoxybutene-3 reveal species differences between rats and mice sensitive to butadiene-induced carcinogenesis

Comparative investigations of inhalation pharmacokinetics of 1,2-epoxybutene-3 (vinyl oxirane, the primary reactive intermediate of butadiene) revealed major differences in metabolism of this compound between rats and mice. Whereas in rats no indication of saturation kinetics of epoxybutene metabolism could be observed up to exposure concentrations of 5000 ppm, in mice saturation of epoxybutene metabolism becomes apparent at atmospheric concentrations of about 500 ppm. The estimated maximal metabolic rate (Vmax) in mice for epoxybutene was only 350 μmol×h−1×kg−1 (rats: >2600 μmol× h−1×kg−1). In the lower concentration range where first order metabolism applies (up to about 500 ppm) epoxybutene is metabolized by mice at higher rates compared to rats (metabolic clearance per kg body weight, mice: 24900 ml×h−1, rats: 13400 ml×h−1). Under these conditions the steady state concentration of epoxybutene in the mouse is about 10 times that in the rat. When mice are exposed to high concentrations of butadiene (>2000 ppm; conditions of saturation of butadiene metabolism; closed exposure system) epoxybutene is exhaled by the animals, and its concentration in the gas phase increases with exposure time. At about 10 ppm epoxybutene signs of acute toxicity are observed. When rats are exposed to butadiene under similar conditions, the epoxybutene concentration reaches a plateau at about 4 ppm. Under these conditions hepatic non-protein sulfhydryl compounds are virtually depleted in mice but not in rats. We conclude that in addition to the higher rate of metabolism of butadiene in mice, limited detoxification and consequently accumulation of its primary reactive intermediate epoxybutene may be a major determinant for the higher susceptibility of mice to butadiene-induced carcinogenesis.

Evaluation of DNA damage by alkaline elution technique after inhalation exposure of rats and mice to 1,3-butadiene

The alkaline filter elution technique was used to evaluate single strand breaks (SSB), DNA-DNA (DDCL) and DNA-protein cross-links (DPCL) in liver and lung of male rats (Sprague-Dawley) and male mice (B6C3F1) after exposure to 2000 ppm 1,3-butadiene (BD) for 7 days (7 h/day and/or to 100, 250, 500, 1000) 2000 ppm BD for 7 h. SSB were detected in liver DNA of both species at 2000 ppm. Cross-links are more pronounced in mouse lung than in mouse liver. Elution rates of lung DNA from mice exposed for 7 h to different concentrations of BD revealed an increase in cross-links between 250 and 500 ppm, and a further increase in cross-links up to 2000 ppm. No such signs of genotoxicity could be observed for the lung of rats. Our data support the involvement of reactive metabolites (epoxybutene and especially diepoxybutane) in butadieneinduced carcinogenesis in the mouse but not to that extent in the rat.

Concentration-dependent depletion of non-protein sulfhydryl (NPSH) content in lung, heart and liver tissue of rats and mice after acute inhalation exposure to butadiene

The effects of different exposure concentrations of butadiene on the cellular non-protein sulfhydryl (NPSH) content of liver, lung and heart tissue were investigated in B6C3F1 mice and Sprague-Dawley rats. Groups of male animals of both species were exposed for 7 h to 10, 50, 100, 250, 500, 1000 and 2000 ppm butadiene. Immediately after exposure, NPSH content of liver, lung and heart tissue was determined according to a modified Ellman procedure. A comparison of both species shows that a dose-dependent NPSH depletion can be observed in mice for all tissues examined. In rats, liver NPSH content shows a major reduction at high exposure concentrations only. In mice, depletion of NPSH content of liver, lung and heart tissue starts at exposure concentrations of about 250 ppm butadiene. A reduction in NPSH content of about 80% is observed for lung tissue at 1000 ppm and for liver and heart tissue at exposure concentrations of 2000 ppm butadiene. The data on tissue concentrations of NPSH obtained after exposure of rats and mice to butadiene reflect the quantitative differences in butadiene metabolism and in biological effectivity of reactive butadiene intermediates between both species.

DNA-binding assay of methyl chloride

Fischer-344 rats and B6C3F1 mice of both sexes were exposed in closed chambers to 14C-labeled methyl chloride. Different clearance values from the gas phase of the system indicated that, based on body weight, mice metabolized the test compound much faster than rats. After isolation of DNA and nucleoproteins from liver and kidneys radioactivity was found in all macromolecular samples; this was ascribed to metabolic C1-incorporation. Radioactivity incorporation was particularly high in DNA of mouse kidneys, suggesting a high turnover to active C1 bodies (formaldehyde, formate) in this tissue.Analyses of DNA samples from kidneys of female and male mice showed neither 7-N-methylguanine nor O6-methylguanine. Hence, the formation of tumors in B6C3F1 mice exposed to high concentrations of methyl chloride is not based on methylation of DNA in this tissue.

Depletion of hepatic non-protein sulfhydryl content during exposure of rats and mice to butadiene

B6C3F1 mice, Sprague-Dawley and Wistar rats were exposed to 1,3-butadiene in a closed exposure system. Exposure concentrations were kept above 2000 ppm to ensure saturation of butadiene metabolism in both species (Vmax conditions). Hepatic non-protein sulfhydryl (NPSH) content was determined in butadiene-exposed animals (and air-exposed controls) after exposures for 0, 7 and 15 h. Depletion of hepatic NPSH content was different for the species and strains investigated. In mice, hepatic NPSH content declined to about 20% after 7 h and was further depleted to about 4% at 15 h when signs of acute toxicity were observed. After a 7 h exposure of rats to butadiene, hepatic NPSH content was depleted to about 65% (Wistar) or 80% (Sprague-Dawley) of the corresponding controls but remained practically stable after a 15 h exposure to butadiene. The time-courses of depletion by butadiene of hepatic NPSH support previous findings on differences in butadiene metabolism between rats and mice and offer an additional explanation for the considerable species differences observed in the toxicity and carcinogenicity of this compound.

DNA adducts of halogenated hydrocarbons

SummaryAlthough formation of DNA adducts has been postulated for several halomethanes, no chemical identification of such adducts has been performed so far. There is, however, evidence that methyl chloride does not act biologically as a DNA methylating agent. 1,2-Dichloroethane and 1,2-dibromoethane are activated through conjugation with glutathione. There is some evidence for formation on an N-7 adduct of guanine which carries an ethyl-S-cysteinyl moiety.Extensive work has been published on adducts of vinyl chloride, both in vitro and in vivo. The major DNA adduct is 7-(2-oxoethyl)guanine; a minor adduct appears to be N2,3-ethenoguanine. Other “etheno” adducts, i.e., 1,N6-ethenoadenine and 3,N4-ethenocytosine, are readily formed with DNA, vinyl chloride, and a metabolizing system in vitro and with RNA in vivo, but are usually not detected as DNA adducts in vivo.The data on DNA alkylation by vinyl chloride (and vinyl bromide) metabolites are compared with those of structurally related compounds (acrylonitrile, vinyl acetate, vinyl carbamate).

Detection of diepoxybutane-induced DNA-DNA crosslinks by cesium trifluoracetate (CsTFA) density-gradient centrifugation

The purpose of our study was to establish the suitability of cesium trifluoroacetate (CsTFA) isopycnic centrifugation as a method for the detection and quantification of DNA-DNA crosslinks (DDC). Rodent liver DNA treated with different concentrations of diepoxybutane and liver DNA of mice and rats exposed to high concentrations of butadiene were investigated

Metabolic transformation of halogenated and other alkenes — a theoretical approach. Estimation of metabolic reactivities for in vivo conditions

Olefinic hydrocarbons are metabolized in vivo by cytochrome P450-dependent monooxygenases to the corresponding epoxides. The maximum in vivo metabolic rate, which is an important toxicokinetic parameter, has been used to define the apparent rate constant (kapp) describing in vivo metabolic reactivity of alkenes. To derive kapp, the metabolic rate normalized per body weight was divided by the corresponding average alkene concentration in the body at saturation conditions of 90%. Toxicokinetic data obtained in rats for 13 compounds (ethene, 1-fluoroethene, 1,1-difluoroethene, 1-chloroethene, 1,1-dichloroethene, cis-1,2-dichloroethene, trans-1,2-dichloroethene, 1,1,2-trichloroethene, perchloroethene, propene, isoprene, 1,3-butadiene and styrene) have been used to calculate kapp values. A theoretical model, based on the assumption that in vivo epoxidation can be described as a cytochrome P450-mediated electrophilic reaction, has been developed. Using the olefinic hydrocarbons as an example it has been shown that kapp can be explained solely by the following molecular parameters: ionization potential, dipole moment and pi-electron density. These molecular parameters were calculated by a quantum chemical method or were taken from the literature. Furthermore, the model was tested also by predicting kapp for isobutene, an alkene which was not used for the model development. The predicted value of kapp agrees with the one derived experimentally, demonstrating that molecular parameters of halogenated and other alkenes can be used to predict in vivo metabolic reactivity. The model presented here is a first contribution to the ultimate goal to predict toxicokinetic parameters for in vivo conditions based on physicochemical parameters of enzymes and compounds exclusively.